Insurance

How to Appeal an Insurance Denial for GLP-1

GLP-1 Companion · 9 min read

Insurance denials for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are common — and frequently overturned on appeal. If you or your prescriber received a denial letter, do not assume the decision is final. Federal law gives you the right to appeal any adverse coverage decision, and insurers reverse a significant share of denials when patients submit a well-documented appeal. This guide walks you through exactly how to do that.

Why GLP-1 Medications Get Denied

Before building your appeal, it helps to understand the most common reasons insurers deny GLP-1 prescriptions. Your denial letter should include a specific reason code or explanation; use that as your starting point.

• BMI does not meet threshold: Many plans require a BMI of 30 or higher, or 27 or higher with a documented comorbidity. If your BMI was recorded differently in the system than in your chart, this can trigger a denial.
• No documented comorbidity: For the BMI-27 pathway, plans require an active diagnosis of a qualifying condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
• Step therapy requirement not met: Some plans require documentation that you tried and failed at least one other weight-loss intervention — typically a structured diet program, behavioral counseling, or a lower-cost medication — before approving a GLP-1.
• Medication prescribed off-label: If Ozempic (approved for type 2 diabetes) was prescribed primarily for weight loss, some plans will deny it, expecting Wegovy (approved for obesity) to be used instead, or vice versa.
• Missing or incomplete documentation: Prior authorization paperwork submitted without adequate clinical notes, lab values, or diagnosis codes frequently results in automatic denial.
• Not on formulary: The specific drug requested may not be on your plan's preferred drug list, requiring an exception request rather than a standard prior auth.

Step 1: Request the Full Denial Explanation

As soon as you receive a denial, call your insurance company and request the complete reason for denial in writing if you have not already received it. Ask specifically which clinical criteria were not met and which policy or clinical guideline the insurer used to make its decision. This information is required for your appeal and must be provided upon request under the Affordable Care Act.

Step 2: File an Internal Appeal

An internal appeal asks the insurance company to review its own decision. Most plans allow up to 180 days from the denial date to file an internal appeal, though submitting sooner is always better. Plans are required to respond to standard internal appeals within 30 to 60 days and to expedited appeals within 72 hours when a health condition makes the standard timeline unreasonable.

1. Write a formal appeal letter addressed to the plan's appeals department. Include your name, member ID, claim or prior auth reference number, and a clear statement that you are appealing the denial.
2. State specifically which criterion the insurer says was not met and explain why the clinical evidence supports coverage.
3. Attach all supporting documentation (see the documentation checklist below).
4. Ask your prescriber to submit a letter of medical necessity simultaneously — insurer representatives weigh physician input heavily.
5. Send the appeal by certified mail or through the insurer's secure online portal so you have a timestamped record.

Documentation Checklist for Your Appeal

A well-documented appeal is far more likely to succeed than a bare letter. Gather as many of the following as apply to your situation.

• BMI records from at least two recent office visits, with dates and measurement methodology noted
• Active diagnosis codes for all qualifying comorbidities (e.g., E11 for type 2 diabetes, I10 for hypertension, E78 for dyslipidemia, G47.33 for sleep apnea)
• Lab results supporting comorbidity diagnoses (HbA1c, fasting glucose, lipid panel)
• Documentation of prior diet and exercise interventions with dates, duration, and outcomes
• Records from any prior weight-loss medications tried, including dose, duration, and reason for discontinuation
• Any behavioral or nutritional counseling records
• Peer-reviewed literature or clinical guidelines (such as AHA/ACC or Obesity Medicine Association guidelines) supporting GLP-1 use for your specific clinical profile
• A letter of medical necessity from your prescribing physician

What to Include in the Prescriber's Letter of Medical Necessity

The prescriber letter is often the most influential document in an appeal. Ask your doctor to include the following elements.

• Your documented BMI with measurement date
• All active obesity-related comorbidities with ICD-10 diagnosis codes
• A summary of prior non-pharmacologic treatments tried and their outcomes
• Any prior pharmacologic treatments tried and why they were insufficient or discontinued
• A clinical rationale for why the specific GLP-1 requested is medically necessary, referencing relevant clinical trial data if applicable
• A statement that the medication is consistent with accepted standards of care for obesity management
• The prescriber's NPI number, signature, and contact information for peer-to-peer review

Step 3: Request a Peer-to-Peer Review

A peer-to-peer review is a direct phone call between your prescriber and the insurance company's medical reviewer. This option is available at most insurers, and many denials are reversed during this call when the prescriber can directly address the reviewer's clinical concerns. Your prescriber must typically request this within a specified window — often five to ten business days of the denial. Encourage your doctor to proactively request a peer-to-peer review alongside or in addition to the written appeal.

Step 4: External Independent Review

If your internal appeal is denied, you have the right to request an external review by an independent organization not affiliated with your insurer. Under the ACA, insurers must comply with external review decisions for most plan types. Studies have shown that patients who pursue external review for medical necessity denials prevail in roughly 40 to 60 percent of cases, making it a worthwhile step when the clinical evidence is strong.

• You generally have 60 days from receipt of the final internal appeal denial to request external review.
• External review organizations are accredited by URAC or NCQA and must make decisions within 45 days for standard reviews and 72 hours for expedited cases.
• If your plan is governed by ERISA (most employer-sponsored plans), your state insurance commissioner can direct you to the appropriate external review entity.
• For ACA marketplace plans, the federal external review program is available as a fallback if your state does not have an approved process.

What to Do While Your Appeal Is Pending

The appeal process can take weeks. In the meantime, ask your prescriber about manufacturer savings programs or patient assistance options that may allow you to start or continue treatment at reduced cost during the review period. Some patients also ask their prescriber to try a different GLP-1 that may be on the plan's preferred formulary, which can be approved more quickly than the initially requested drug.

Persistence matters. Multiple studies of insurance appeal data show that the majority of GLP-1 denials that are formally appealed with complete documentation are ultimately reversed. The appeal process exists precisely because initial determinations are frequently made without full clinical context.

Key Takeaways

A GLP-1 denial is a starting point, not a final answer. Most denials stem from missing documentation rather than a genuine lack of clinical need. By assembling strong evidence, involving your prescriber actively, and following the internal and external appeal steps in order, you substantially increase the likelihood of a favorable outcome. Keep copies of everything you submit and document every phone call with a date, time, and representative name.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.